RELMADA THERAPEUTICS, INC. — All Filings
581 total filings on record
Public companies registered with the SEC are required to file periodic reports, disclosures, and notices throughout the year. The most important are the 10-K (annual report), 10-Q (quarterly report), and 8-K (material event notice). Use the filters below to narrow by form type.
All
10-K
10-KT
10-Q
144
3
3/A
4
4/A
424B3
424B5
5
5/A
8-A12B
8-A12G
8-K
8-K/A
CERT
CORRESP
D
D/A
DEF 14A
DEFA14A
DFAN14A
EFFECT
FWP
NT 10-K
NT 10-Q
POS AM
PRE 14A
S-1
S-1/A
S-3
S-3/A
S-3ASR
S-8
SC 13D
SC 13D/A
SC 13G
SC 13G/A
SCHEDULE 13G
SCHEDULE 13G/A
SEC STAFF ACTION
UPLOAD
| Form | Description | Accession Number | Filed | Period |
|---|---|---|---|---|
| 8-K | CURRENT REPORT | 0001213900-25-042024 | May 12, 2025 | May 8, 2025 |
| 10-Q | QUARTERLY REPORT | 0001213900-25-042025 | May 12, 2025 | Mar 31, 2025 |
| SCHEDULE 13G | — | 0002050709-25-000003 | May 1, 2025 | — |
| 8-K | CURRENT REPORT | 0001213900-25-035941 | Apr 28, 2025 | — |
| 424B5 | PROSPECTUS SUPPLEMENT | 0001213900-25-035961 | Apr 28, 2025 | — |
| DEFA14A | DEFINITIVE ADDITIONAL MATERIALS | 0001213900-25-031095 | Apr 11, 2025 | — |
| DEF 14A | PROXY STATEMENT | 0001213900-25-031088 | Apr 11, 2025 | May 23, 2025 |
| 8-K | CURRENT REPORT | 0001013762-25-003432 | Mar 27, 2025 | — |
| 10-K | ANNUAL REPORT | 0001013762-25-003426 | Mar 27, 2025 | Dec 31, 2024 |
| 8-K | CURRENT REPORT | 0001013762-25-002786 | Mar 26, 2025 | Mar 24, 2025 |
| 8-K | CURRENT REPORT | 0001213900-25-010711 | Feb 6, 2025 | Feb 3, 2025 |
| 8-K | CURRENT REPORT | 0001213900-25-006727 | Jan 27, 2025 | Jan 21, 2025 |
| 8-K | CURRENT REPORT | 0001213900-25-001249 | Jan 6, 2025 | Jan 1, 2025 |
| 8-K | CURRENT REPORT | 0001213900-24-106646 | Dec 9, 2024 | — |
| 8-K | CURRENT REPORT | 0001213900-24-105245 | Dec 4, 2024 | — |
| SC 13G/A | — | 0001172661-24-004766 | Nov 14, 2024 | — |
| 10-Q | QUARTERLY REPORT | 0001213900-24-095398 | Nov 7, 2024 | Sep 30, 2024 |
| 4 | — | 0001213900-24-089971 | Oct 23, 2024 | Oct 22, 2024 |
| EFFECT | — | 9999999995-24-002821 | Sep 12, 2024 | — |
| 4 | OWNERSHIP DOCUMENT | 0001213900-24-077795 | Sep 11, 2024 | Sep 9, 2024 |
| 4 | — | 0001213900-24-077792 | Sep 11, 2024 | Sep 9, 2024 |
| 4 | — | 0001213900-24-077794 | Sep 11, 2024 | Sep 9, 2024 |
| CORRESP | — | 0001213900-24-077748 | Sep 11, 2024 | — |
| 4 | — | 0001213900-24-077791 | Sep 11, 2024 | Sep 9, 2024 |
| UPLOAD | — | 0000000000-24-010111 | Sep 6, 2024 | — |
| S-3 | REGISTRATION STATEMENT | 0001213900-24-074553 | Aug 30, 2024 | — |
| 10-Q | QUARTERLY REPORT | 0001213900-24-066111 | Aug 7, 2024 | Jun 30, 2024 |
| 8-K | CURRENT REPORT | 0001213900-24-047968 | May 30, 2024 | May 24, 2024 |
| 4 | — | 0001213900-24-047639 | May 29, 2024 | May 24, 2024 |
| 4 | — | 0001213900-24-047636 | May 29, 2024 | May 24, 2024 |
| 4 | — | 0001213900-24-047632 | May 29, 2024 | May 24, 2024 |
| 4 | — | 0001213900-24-047637 | May 29, 2024 | May 24, 2024 |
| 4 | — | 0001213900-24-047635 | May 29, 2024 | May 24, 2024 |
| 4 | — | 0001213900-24-047638 | May 29, 2024 | May 24, 2024 |
| 4 | — | 0001213900-24-047633 | May 29, 2024 | May 24, 2024 |
| 10-Q | QUARTERLY REPORT | 0001213900-24-040856 | May 8, 2024 | Mar 31, 2024 |
| DEFA14A | DEFINITIVE ADDITIONAL MATERIALS | 0001213900-24-031609 | Apr 9, 2024 | — |
| DEF 14A | PROXY STATEMENT | 0001213900-24-031600 | Apr 9, 2024 | May 24, 2024 |
| 8-K | CURRENT REPORT | 0001213900-24-024022 | Mar 19, 2024 | — |
| 10-K | ANNUAL REPORT | 0001213900-24-024013 | Mar 19, 2024 | Dec 31, 2023 |
| SC 13G/A | SC 13G/A | 0001193125-24-060735 | Mar 6, 2024 | — |
| 144 | — | 0001972362-24-000160 | Feb 20, 2024 | — |
| SC 13G/A | RELMADA THERAPEUTICS, INC. | 0000902664-24-001574 | Feb 14, 2024 | — |
| SC 13G/A | — | 0001172661-24-000937 | Feb 14, 2024 | — |
| SC 13G/A | SCHEDULE 13G/A | 0001104659-24-021823 | Feb 13, 2024 | — |
| 4 | — | 0001213900-24-008557 | Jan 31, 2024 | Jan 29, 2024 |
| 4 | — | 0001213900-24-008559 | Jan 31, 2024 | Jan 29, 2024 |
| 4 | — | 0001213900-24-008560 | Jan 31, 2024 | Jan 29, 2024 |
| 8-K | CURRENT REPORT | 0001213900-24-003000 | Jan 11, 2024 | Jan 5, 2024 |
| 8-K | CURRENT REPORT | 0001213900-24-000999 | Jan 4, 2024 | — |